Thermo Fisher Scientific Inc. $TMO Shares Acquired by CW Advisors LLC

CW Advisors LLC lifted its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 30,432 shares of the medical research company’s stock after purchasing an additional 1,472 shares during the period. CW Advisors LLC’s holdings in Thermo Fisher Scientific were worth $12,339,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of TMO. Brighton Jones LLC lifted its stake in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock worth $255,000 after buying an additional 20 shares during the last quarter. Advyzon Investment Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 1st quarter valued at about $126,000. Empower Advisory Group LLC grew its position in shares of Thermo Fisher Scientific by 1.7% during the 1st quarter. Empower Advisory Group LLC now owns 18,832 shares of the medical research company’s stock valued at $9,371,000 after buying an additional 319 shares during the last quarter. Finally, Wealthspire Advisors LLC lifted its holdings in Thermo Fisher Scientific by 0.8% in the first quarter. Wealthspire Advisors LLC now owns 8,073 shares of the medical research company’s stock worth $4,017,000 after acquiring an additional 66 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on TMO. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an “outperform” rating for the company. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research report on Tuesday, September 2nd. Leerink Partners boosted their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. TD Cowen increased their price objective on shares of Thermo Fisher Scientific from $612.00 to $654.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, Hsbc Global Res raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research note on Monday. One investment analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $602.35.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction dated Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the completion of the transaction, the chief executive officer owned 113,762 shares in the company, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, VP Lisa P. Britt sold 10,225 shares of the business’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $571.62, for a total transaction of $5,844,814.50. Following the completion of the sale, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. The trade was a 41.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 65,625 shares of company stock valued at $38,157,158. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.0%

Thermo Fisher Scientific stock opened at $580.61 on Thursday. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $610.97. The stock has a market cap of $218.14 billion, a price-to-earnings ratio of 33.54, a PEG ratio of 4.28 and a beta of 0.90. The company’s 50-day moving average price is $555.23 and its two-hundred day moving average price is $483.27. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period last year, the firm posted $5.28 earnings per share. The business’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s payout ratio is currently 9.94%.

Thermo Fisher Scientific declared that its board has initiated a stock buyback program on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s board believes its stock is undervalued.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.